The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer

Bookmark and Share
Published: 19 Dec 2019
Views: 810
Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain

Dr Miguel Martín speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the PEARL study updated results.

The PEARL study did not show a statistically superiority in PFS for PAL ET vs capecitabine in MBC patients, and Martín explains why this might have been.

From this, he explains what the next steps must be in order to continue combatting this disease.